Organogenesis Holdings (ORGO) Net Income towards Common Stockholders (2016 - 2026)

Organogenesis Holdings has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$99.3 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 714.12% year-over-year to -$99.3 million in Q2 2026; TTM through Jun 2026 was -$100.2 million, a 542.91% decrease from a year earlier, with the FY2025 full-year figure at $25.7 million, up 2838.74% from the prior year.
• Net Income towards Common Stockholders was -$99.3 million for Q2 2026 at Organogenesis Holdings, down from -$56.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $40.8 million in Q4 2025, with the low at -$99.3 million in Q2 2026.
• Average Net Income towards Common Stockholders over 5 years is -$6.4 million, with a median of -$176500.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 1373.02% in 2023, then sank 928.14% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $7.5 million in 2022, then slumped by 107.59% to -$568000.0 in 2023, then soared by 1134.33% to $5.9 million in 2024, then soared by 593.82% to $40.8 million in 2025, then sank by 343.7% to -$99.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$99.3 million (Q2 2026), -$56.2 million (Q1 2026), and $40.8 million (Q4 2025), per Business Quant data.